M. Mahjoubi

发表

Hepatic arterial infusion using pirarubicin combined with systemic chemotherapy: a phase II study in patients with nonresectable liver metastases from colorectal cancer.

P. Couzigou, M. Ychou, M. Ducreux, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

CPT-11 (irinotecan) in the treatment of colorectal cancer.

M. Ducreux, P. Hérait, P. Rougier, 1995, European journal of cancer.

Pathophysiology and therapy of irinotecan-induced delayed-onset diarrhea in patients with advanced colorectal cancer: a prospective assessment.

G. Vassal, P. Hérait, J. Misset, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II trial of LY 186641 in advanced renal cancer

J. Droz, J. Kattan, M. Bonnay, 1993, Investigational New Drugs.

M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced carcinoma of the bladder. The French Federation of Cancer Centers experience.

J. Droz, M. Spielmann, P. Fargeot, 1991, European journal of cancer.

92 CPT 11 (Irinotecan) in pretreated small cell lung cancer (SCLC): A phase II study in patients progressing after a first response (preliminary results)

J. Pujol, J. Douillard, T. Chevalier, 1995 .

Neoadjuvant chemotherapy (NCT) in locally advanced gastric carcinoma (LAGC)

J. Pignon, M. Ducreux, P. Rougier, 1993 .

Phase II trial with etoposide (VP16) plus ifosfamide plus high-dose cisplatin (VIhP regimen) in refractory germ cell tumors.

C. Théodore, J. Droz, V. Ribrag, 1989, Progress in clinical and biological research.

Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy.

S. Culine, T. Conroy, M. Ychou, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I and pharmacokinetic study of irinotecan (CPT-11) administered daily for three consecutive days every three weeks in patients with advanced solid tumors.

A. Gouyette, G. Chabot, J. Guastalla, 1995, Annals of oncology : official journal of the European Society for Medical Oncology.

Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials.

S. Culine, P. Hérait, J. Armand, 1995, Annals of oncology : official journal of the European Society for Medical Oncology.

Factors predicting for efficacy and safety of docetaxel in a compassionate-use cohort of 825 heavily pretreated advanced breast cancer patients.

J. Bonneterre, P. Viens, S. Faivre, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Neoadjuvant chemotherapy in locally advanced gastric carcinoma--a phase II trial with combined continuous intravenous 5-fluorouracil and bolus cisplatinum.

J. Pignon, M. Ychou, M. Ducreux, 1994, European journal of cancer.

742 Pathophysiology and therapy of irinotecan (CPT-11) induced delayed onset diarrhea (DD): A prospective assessment

G. Vassal, P. Hérait, S. Giacchetti, 1995 .

Severe CPT-11 toxicity in patients with Gilbert's syndrome: two case reports.

F. Goldwasser, J. Misset, F. Trivin, 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

Short report Severe CPT-11 toxicity in patients with Gilbert's syndrome: Two case reports

F. Goldwasser, F. Trivin, J. Misset, 2005 .

High dose-intensity of irinotecan administered every 3 weeks in advanced cancer patients: a feasibility study.

P. Hérait, J. Armand, M. Marty, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Preoperative chemotherapy of locally advanced gastric cancer.

M. Ducreux, P. Rougier, D. Elias, 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

Irinotecan combined with bolus fluorouracil, continuous infusion fluorouracil, and high-dose leucovorin every two weeks (LV5FU2 regimen): a clinical dose-finding and pharmacokinetic study in patients with pretreated metastatic colorectal cancer.

M. Ychou, M. Ducreux, P. Rougier, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy of combined 5-fluorouracil and cisplatinum in advanced gastric carcinomas. A phase II trial with prognostic factor analysis.

J. Pignon, M. Ychou, M. Ducreux, 1994, European journal of cancer.

Factors P redicting f or E fficacy a nd S afety o f D ocetaxel i n a C ompassionate-Us e C ohort o f 8 25 H eavily P retreated Advanced B reast C ancer P atients

J. Bonneterre, P. Viens, S. Faivre, 2000 .

Efficacy and safety of docetaxel (Taxotere) in heavily pretreated advanced breast cancer patients: the French compassionate use programme experience.

M. Namer, J. Bonneterre, L. Mauriac, 1999, European journal of cancer.

Combination of oxaliplatin plus irinotecan in patients with gastrointestinal tumors: results of two independent phase I studies with pharmacokinetics.

F. Goldwasser, M. Marty, J. Misset, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of cisplatin and 120-hour continuous infusion of 5-fluorouracil in patients with advanced pancreatic adenocarcinoma.

J. Pignon, M. Ducreux, P. Rougier, 1993, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II trial of ifosfamide in the treatment of metastatic hormone-refractory patients with prostatic cancer.

C. Théodore, J. Droz, M. Ghosn, 1990, Cancer investigation.

Phase I Study of Retelliptine Dihydrochloride (SR 95325 B) Using a Single Two‐Hour Intravenous Infusion Schedule

J. Droz, M. Durand, J. Kattan, 1994, American journal of clinical oncology.

Phase II trial of pirarubicin in the treatment of advanced pancreatic cancer.

P. Hérait, P. Rougier, J. Droz, 1994, Cancer investigation.

High failure rate of carboplatin-etoposide combination in good risk non-seminomatous germ cell tumours.

S. Culine, J. Droz, J. Kattan, 1993, European journal of cancer.

Treatment of good-risk disseminated non-seminomatous germ cell tumours: the less bleomycin, the more cisplatin?

S. Culine, J. Droz, M. Mahjoubi, 1991, European journal of cancer.

Original Paper EYcacy and Safety of Docetaxel (Taxotere 2 ) in Heavily Pretreated Advanced Breast Cancer Patients: the French Compassionate Use Programme Experience

M. Namer, J. Bonneterre, L. Mauriac, 1999 .

Phase II trial of pirarubicin in the treatment of advanced bladder cancer

P. Hérait, J. Droz, J. Kattan, 1992, Investigational New Drugs.

Feasibility trial of a combination of vinorelbine, ifosfamide, fluorouracil and folinic acid (VIF regimen) in advanced urothelial cancer.

C. Théodore, J. Droz, J. Kattan, 1993, European journal of cancer.